Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Cengiz KaraçinBerna OksuzogluAyşe DemirciMerve KeskinkılıçNaziyet Köse BaytemürFunda YılmazOğuzhan SelviDilek ErdemEsin AvşarNail PaksoyNecla DemirSema Sezgin GöksuSema TürkerErtuğrul BayramAbdüssamet ÇelebiHatice YılmazÖmer Faruk KuzuSeda Kahramanİvo GökmenAbdullah SakinAli AlkanErdinç NayırMuzaffer UğraklıÖmer Acarİsmail ErtürkHacer DemirFerit AslanÖzlem SönmezTaner KorkmazÖzde Melisa Celayirİbrahim KaradağErkan KayıkçıoğluTeoman Şakalarİlker Nihat ÖktemTülay ErenEnes UrulEda Eylemer MocanZiya KalkanNilgün YıldırımYakup ErgünBaran AkagündüzSerdar KarakayaEngin KutFatih TekerBurçin Çakan DemirelKubilay KaraboyunElvina AlmuradovaOlçun Ümit ÜnalAbdilkerim OymanDeniz IşıkKerem OkuturBuğra ÖztosunBurcu Belen GülbağcıMehmet Emin KalenderElif ŞahinMustafa SeyyarÖzlem ÖzdemirFatih SelçukbiricikMetin Kanıtezİsa DedeMahmut GümüşErhan GökmenArzu YarenSerkan MenekşeSenar EbinçSercan AksoyGökşen İnanç İmamoğluMustafa AltınbaşBülent ÇetinBaşak Oyan UluçÖzlem ErNuri KaradurmuşAtike Pınar ErdoğanMehmet ArtaçÖzgür Tanrıverdiİrfan ÇiçinMehmet Ali Nahit ŞendurEsin Oktayİbrahim Vedat BayoğluSemra PaydaşAdnan AydınerDerya Kıvrak SalimÇağlayan GeredeliTuğba YavuzşenMutlu Doğanİlhan HacıbekiroğluPublished in: BMC cancer (2023)
Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.